Current NIAID Biodefense Research Funding Opportunities
Basic Research
Research to Advance Vaccine Safety
Focus: This research opportunity invites studies that address scientific areas potentially relevant to vaccine safety such as 1) physiological and immunological responses to vaccines and vaccine components, 2) how genetic variations affect immune/physiological responses that may impact vaccine safety, 3) identification of risk factors and biological markers that may be used to assess whether there is a relationship between certain diseases or disorders and licensed vaccines, or 4) the application of genomic/molecular technologies to improve knowledge of vaccine safety.
Contact Info:
Barbara Mulach, Ph.D.
National Institute of Allergy and Infectious Diseases
E-mail: bmulach@niaid.nih.gov
Alice Kau, Ph.D.
Eunice Kennedy Shriver National Institute of Child Health and Human Development
E-mail:kaua@mail.nih.gov
Cindy P. Lawler
National Institute of Environmental Health Sciences
E-mail: lawler@niehs.nih.gov
Lisa Gilotty, Ph.D.
National Institute of Mental Health
Email: gilottyl@mail.nih.gov
Karen Huss, Ph.D.
National Institute of Nursing Research
Email: hussk@mail.nih.gov
Juliana K. Cyril, PhD, MPH
National Center for Chronic Disease Prevention and Health Promotion
Email: jcyril@cdc.gov
Focus: Research aimed at developing tools to control epidemic influenza and the increasing threat of pandemic influenza is one of NIAID's highest priorities. Areas of high priority include, but are not limited to, the following:
- Development of improved drugs against influenza, including structure/function studies of influenza virus proteins with the goal of identifying new therapeutic targets.
- The development of novel influenza vaccines and vaccination strategies. Novel approaches might include developing and evaluating new vaccine formulations, adjuvants, immune response stimulators, protective T-cell and antibody epitopes, new routes of delivery, common epitope vaccines, and alternatives to egg-based vaccine production technologies.
- The development of sensitive, specific, and rapid clinical diagnostic tests for influenza.
- Evaluation of the immune response to infection and/or vaccination including cell-mediated and innate immunity.
- Determination of the molecular basis of virulence of influenza viruses in humans and animals.
- Evaluation of the molecular and/or environmental factors that influence the transmission of influenza viruses, including drug-resistant strains.
- Studies on the evolution and emergence of influenza viruses, including the identification of factors that affect influenza host-range and virulence.
- Virologic and serologic surveillance studies of the distribution of influenza viruses with pandemic potential in animal populations and in humans at the human/animal interface.
Standard receipt dates
Focus: Basic and applied research on NIAID Category A, B, and C Priority Pathogens, their toxic products, and the body's immune defenses against them.
Contact Info
Sam Perdue
E-mail: sperdue@niaid.nih.gov
Standard receipt dates
Focus: To support a discrete, specified, circumscribed project to be performed by the named investigator(s) in areas representing the specific interests and competencies of the investigator(s).
Contact Info
Sam Perdue
E-mail: sperdue@niaid.nih.gov
Standard receipt dates
Focus: Small research projects; funding for up to 2 years, not specific to bioterrorism, but bioterrorism-related research is responsive.
Contact Info
Sam Perdue
E-mail: sperdue@niaid.nih.gov
Alison Deckhut
E-mail: adeckhut@niaid.nih.gov
Standard receipt dates
Focus: To foster the introduction of novel scientific ideas, model systems, tools, agents, targets, and technologies that have the potential to substantially advance biomedical research.
Contact Info
Allan Czarra
E-mail: aczarra@niaid.nih.gov
back to top